Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis
By Lori Solomon HealthDay Reporter
FRIDAY, Oct. 4, 2024 -- Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ulcerative colitis than placebo, according to a phase 2 study published in the Sept. 26 issue of the New England Journal of Medicine.
Bruce E. Sands, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned 135 patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis to receive intravenous tulisokibart (1,000 mg on day 1 and 500 mg at weeks 2, 6, and 10) or placebo. Cohort 1 included patients regardless of genetic status, and cohort 2 included only 43 patients with a positive test for likelihood of response.
The researchers found that a significantly higher percentage of patients who received tulisokibart had clinical remission than those who received placebo (26 versus 1 percent). Among 75 patients with a positive test for likelihood of response (across cohorts), clinical remission occurred in a higher percentage of patients who received tulisokibart versus those who received placebo (32 versus 11 percent). The incidence of adverse events was similar in the tulisokibart and placebo groups, with most adverse events mild to moderate in severity.
"Additional evaluation and comparisons in larger patient populations are needed to further assess the value of the diagnostic test," the authors write.
The study was funded by Prometheus Biosciences, a subsidiary of Merck, which is developing tulisokibart.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Healthy Plant-Based Diet May Lower Inflammatory Bowel Disease Risk
WEDNESDAY, July 16, 2025 -- A healthy plant-based diet may reduce the risk for inflammatory bowel disease (IBD) due to the anti-inflammatory properties of the diet, according to a...
Increase in Chronic Digestive Disorders Seen During Pandemic
WEDNESDAY, July 9, 2025 -- There was an increase in disorders of gut-brain interaction (DGBI) during the COVID-19 pandemic for those living in the United States, according to a...
Most TikTok Videos on Inflammatory Bowel Disease Are Low Quality
FRIDAY, June 13, 2025 -- The most-viewed inflammatory bowel disease (IBD) videos on TikTok provide low-quality medical information, according to a study published online in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.